CLSP 5282 for Solid Tumors
What You Need to Know Before You Apply
What is the purpose of this trial?
Phase 1, open-label, multicenter study to evaluate the safety, tolerability, PK, PD, and preliminary clinical activity of CLSP 5282 when administered to HLA A\*03:01-positive adult patients with advanced solid tumors that harbor the KRas G12V mutation.
Who Is on the Research Team?
Lauren Harshman, MD
Principal Investigator
Clasp Therapeutics
Are You a Good Fit for This Trial?
This trial is for adults with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic marker (KRas G12V mutation) and are HLA-A*03:01 positive. Participants must be in generally good health aside from their cancer.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- CLSP-5282
Trial Overview
The study is testing a new drug called CLSP-5282 to see if it is safe and how the body responds to it. All participants will receive this drug. The trial is early-stage and takes place at multiple centers.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Dose expansion of CLSP-5282 in indication-specific cohorts in pancreatic adenocarcinoma (PDAC), colorectal cancer (CRC), and non-small cell lung carcinoma (NSCLC) as well as an all-other solid tumor cohort conducted at the RDE.
Dose Escalation of CLSP-5282 in HLA A\*03:01-positive adult patients with advanced solid tumors that harbor the KRas G12V mutation.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Clasp Therapeutics, Inc.
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.